Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01732770 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis
A Phase 4 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 4
- Development phase
- 643
- Enrollment target
NCT01732770 is a Phase 4 study that has completed, run by Amgen. The registered enrollment target is 643 participants.
The verdict
NCT01732770, a Phase 4 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 643 participants
- Enrollment target
Study Summary
This study will compare the effectiveness of denosumab treatment every 6 months with once yearly zoledronic acid treatment on bone mineral density (BMD) at various skeletal sites.
Interventions
- DRUG Zoledronic Acid
- BIOLOGICAL Denosumab
- DRUG Placebo to Denosumab
- DRUG Placebo to Zoledronic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 643 participants |
| Start Date | 2012-11-07 |
| Est. Completion | 2015-01-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01732770
The ClinicalTrials.gov registry entry for NCT01732770 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 643 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Zoledronic Acid is the first listed.
NCT01732770 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01732770 about?
NCT01732770 is a clinical study titled "Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis". This study will compare the effectiveness of denosumab treatment every 6 months with once yearly zoledronic acid treatment on bone mineral density (BMD) at various skeletal sites.
What is the current status of trial NCT01732770?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 643 participants. The study started on 2012-11-07. Estimated completion is 2015-01-07.
What interventions are being tested in trial NCT01732770?
The interventions under investigation include: Zoledronic Acid (DRUG), Denosumab (BIOLOGICAL), Placebo to Denosumab (DRUG), Placebo to Zoledronic Acid (DRUG).
Who is sponsoring clinical trial NCT01732770?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.